Evaluating the Impact of a Decade of Funding from the Green Chemistry Institute Pharmaceutical Roundtable

• Published in: Organic process research & development Vol. 22; no. 10; pp. 1344 - 1359
• Main Authors: Koenig, Stefan G, Leahy, David K, Wells, Andrew S
• Format: Journal Article
• Language: English
• Published: American Chemical Society 19.10.2018
• Subjects: catalysis; green chemistry; sustainable manufacturing; ACS-GCI Pharmaceutical Roundtable
• ISSN: 1083-6160; 1520-586X
• DOI: 10.1021/acs.oprd.8b00237

Starting in 2007, the ACS Green Chemistry Institute Pharmaceutical Roundtable (GCIPR) has invested in sustainable chemical reactions and technologies in order to positively impact the pharmaceutical manufacturing routes and processes of the future. It has done so by committing over $2 million to support a grant program focused on spurring innovative and sustainable solutions to industrially relevant problems with significant unmet need. This has resulted in the funding of 28 research programs from academic groups across the globe, spanning a wide range of greener chemical technologies such as C–H activation, flow chemistry, biocatalysis, novel catalytic transformations, base metal catalysis, and solvent substitution. The application of this work has encompassed a range of therapeutic modalities, from traditional small molecules to peptides and biologics. This manuscript reviews the impact of the GCIPR funding program in its first decade by drawing together in one place the outputs of each project funded, to serve as a resource for those interested in moving toward more sustainable synthesis of chemical products. Through to 2017, the 28 funded research projects have resulted in 73 publications in peer reviewed scientific journals and have attracted over 1700 unique daughter citations. This publication reviews and showcases the productivity of the funding program and highlights the industrial application of this work toward its goal of more sustainable chemical processes for pharmaceutical products.